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Background: To evaluate the metabolic changes on 18 F-fluoro-2-deoxyglucose positron emission tomography
integrated with computed tomography (18 F-FDG PET-CT) performed before, during and after concurrent chemo-
radiotherapy in patients with locally advanced non-small cell lung cancer (NSCLC); to correlate the metabolic
response with the delivered radiation dose and with the clinical outcome.
Methods: Twenty-five NSCLC patients candidates for concurrent chemo-radiotherapy underwent 18 F-FDG PET-CT
before treatment (pre-RT PET-CT), during the third week (during-RT PET-CT) of chemo-radiotherapy, and 4 weeks
from the end of chemo-radiotherapy (post-RT PET-CT). The parameters evaluated were: the maximum standardized
uptake value (SUVmax) of the primary tumor, the SUVmax of the lymph nodes, and the Metabolic Tumor Volume
(MTV).
Results: SUVmax of the tumor and MTV significantly (p=0.0001, p=0.002, respectively) decreased earlier during the
third week of chemo-radiotherapy, with a further reduction 4 weeks from the end of treatment (p<0.0000,
p<0.0002, respectively). SUVmax of lymph nodes showed a trend towards a reduction during chemo-radiotherapy
(p=0.06) and decreased significantly (p=0.0006) at the end of treatment. There was a significant correlation (r=0.53,
p=0.001) between SUVmax of the tumor measured at during-RT PET-CT and the total dose of radiotherapy reached
at the moment of the scan. Disease progression free survival was significantly (p=0.01) longer in patients with
complete metabolic response measured at post-RT PET-CT.
Conclusions: In patients with locally advanced NSCLC, 18 F-FDG PET-CT performed during and after treatment
allows early metabolic modifications to be detected, and for this SUVmax is the more sensitive parameter. Further
studies are needed to investigate the correlation between the metabolic modifications during therapy and the
clinical outcome in order to optimize the therapeutic strategy. Since the metabolic activity during chemo-
radiotherapy correlates with the cumulative dose of fractionated radiotherapy delivered at the moment of the scan,
special attention should be paid to methodological aspects, such as the radiation dose reached at the time of PET.
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About one third of patients with non-small cell lung can-
cer (NSCLC) present loco-regionally advanced disease at
the diagnosis [1,2], and despite radical treatment with
concurrent chemo-radiotherapy (chemo-RT), only 15%
of patients will be long-term survivors and 15%–40% will
develop loco-regional tumor recurrence [3,4]. A higher
biologically effective dose of radiotherapy can improve
loco-regional control and survival [5]: however, an escal-
ating radiotherapy dose also results in increasing the risk
of toxicity [6]. For this reason, it is important to carefully
select patients for radiotherapy dose intensification. Cur-
rently, the response to radiotherapy is not determined
until the therapy has been completed. If the individual
response to radiotherapy could be evaluated earlier dur-
ing treatment, a timely therapy modification could be
accomplished to better adapt the cure. Molecular im-
aging offers the potential to characterize the nature of
tissues on the basis of its biochemical and biologic fea-
tures. 18 F-fluoro-2-deoxyglucose (18 F-FDG) positron
emission tomography integrated with computed tomog-
raphy (18 F-FDG PET-CT) is largely used in oncology, es-
pecially for monitoring the response to treatment. The
imaging of changes in glucose metabolism, as reflected
by cellular uptake and trapping of 18 F-FDG, can provide
a response assessment that is both more timely and more
accurate than that provided by standard morphological
imaging [7]. Furthermore, the residual metabolic activity
of tumors after radiotherapy, as measured by 18 F-FDG
uptake, has been shown to correlate with the pathologic
response [8], and to be a significant prognostic factor for
survival in patients with NSCLC [9–11]. Many research-
ers recommend a delay of 6–8 weeks or longer after
radiotherapy before performing the post-treatment PET
study because of inflammatory changes with subsequent
alterations in 18 F-FDG uptake [12]. Nevertheless, the
confounding effect in the surrounding normal tissue due
to the radiation-induced elevation of 18 F-FDG activity in
the lung seems to be less relevant when PET is per-
formed during radiotherapy [13]. The objectives of this
study were: to evaluate the metabolic changes on serial
18 F-FDG PET-CT studies performed before, during and
after concurrent chemo-radiotherapy in patients with
unresectable or locally advanced NSCLC; to correlate the
metabolic changes with the delivered radiation dose and
with the clinical outcome.
Methods
Study population
Forty-three patients with unresectable or locally
advanced NSCLC who were referred to our department
from December 2005 to May 2008 were enrolled in this
study. Eligibility criteria were good performance status
(ECOG-performance status of 0 or 1), and a reasonablelung function (a forced expiratory volume in the 1st sec-
ond >50% of predicted value and a diffusing capacity of
the lung for carbon monoxide >50%). Patients were not
eligible if they had any other concomitant malignant dis-
ease, uncontrolled diabetes mellitus, or severe cardiac or
cerebral diseases. Patients having undergone previous
radiotherapy to the chest were not allowed to participate
while those previously submitted to chemotherapy were
accepted. Herein we describe only 25/43 patients (58%,
21 males and 4 females, mean age 64 years, range 43–
78 years) who satisfied the eligibility criteria.
Treatment description
All patients underwent concurrent chemo-RT. In the case
of previous chemotherapy, concurrent chemo-RT was
started after a minimum of 30 days from the last chemo-
therapy course. Radiotherapy was administered to the
involved field with a three-dimensional conformal tech-
nique. The median International Commission on Radi-
ation Units and Measurements (ICRU) total referred dose
was 50.4 Gy with classical (1.8 Gy/day) fractionation. The
planned target volume (PTV) consisted of the primary
tumor and the gross nodal volume. Elective nodal irradi-
ation was not administered. The treatment was planned
with computed tomography, applying the lung paren-
chyma correctional factors. A linear photon accelerator
(nominal energy 6–10 MeV) was used for the treatment in
all cases. All patients were immobilized by customized
devices. Two different concurrent chemotherapy regimens
were used. Cisplatin (CDDP), 20 mg/m2/day/bolus during
days 1–4 of the first and last week of treatment, plus
weekly gemcitabine 350 mg/m2/day, was administered to
patients who had not received previous chemotherapy.
Two hundred and fifty mg/m2/day weekly gemcitabine
alone was delivered to patients who had undergone prior
chemotherapy. A radiological and pneumological re-
assessment was performed 4 weeks from the end of
chemo-radiotherapy. Patients judged operable underwent
surgery, while those considered inoperable were treated
according to the preference of the referring physician.
18 F-FDG PET-CT protocol: acquisition and reconstruction
parameters, and image interpretation
Three 18 F-FDG PET-CT studies were performed using
the same acquisition and reconstruction protocol: before
starting chemo-RT (pre-RT PET-CT), during the third
week of treatment (during-RT PET-CT), and 4 weeks
from the end of treatment (post-RT PET-CT). The pre-
RT PET-CT was performed at a median time of 13 days
(range 1–29 days) before starting chemo-RT; the during-
RT PET-CT was performed after a median time of
17 days from the start of treatment (range 10–25 days)
and after the delivery of a median radiotherapy dose of
23.4 Gy (range 14.4-34.2 Gy); the post-RT PET-CT was
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36 days) from the end of treatment. In case of previous
chemotherapy, at least one month had to pass between
the last administration and the acquisition of the 18 F-
FDG PET-CT. Details of the study were explained to
the patients and they provided written informed con-
sent as established by our ethics committee. All studies
were performed using an integrated 3D PET-CT device
(GEMINI GXL distributed by Philips Medical Systems)
combining a dedicated full-ring PET scanner with
gadolinium-oxyortho-silicate (GSO) crystals and a multi-
slice spiral CT scanner. Prior to 18 F-FDG injection,
patients fasting for at least six hours were settled in a
quiet room, checked to be normoglycemic (patients with
a fasting glucose level >150 mg/dl were excluded), and
intravenously hydrated with saline solution (500 ml). No
oral or intravenous contrast agents were administered or
bowel preparation applied for any patient in our series.
Images were acquired one hour after intravenous injec-
tion of 259–407 MBq of 18 F-FDG, produced in the
radio-pharmacy of our Centre, according to the body
mass index from pelvis to neck. The CT scan, performed
from neck to pelvis with a voltage of 120 KeV and tube
current of 30 mA, was used for the anatomical
localization, and for attenuation correction of PET emis-
sion data. PET emission scans were acquired in 3D
mode, from pelvis to neck (multiple bed positions,
3 minutes for each bed position). Matched CT and PET
images were reconstructed with a field-of-view of 50 cm.
Iterative reconstruction and CT-based attenuation cor-
rection were used and attenuation-corrected PET images
were reviewed in transverse, sagittal and coronal planes.
PET data were also displayed in a rotating maximum-
intensity projection. To view the images, the PET and
CT datasets were transferred to an independent com-
puter workstation by DICOM (Digital Imaging and
Communications in Medicine) transfer. PET-CT images
were analyzed semi-quantitatively using the Syntegra
Philips fusion program by two nuclear medicine physi-
cians (M.L.C and M.G.S) with PET-CT experience. Re-
gions of interest (ROIs) were manually drawn over the
lesions (tumor and lymph nodes) showing an 18 F-FDG
uptake higher than background activity. The Standar-
dized Uptake Value (SUV) was measured in all voxels in
the tumor ROI: SUV= (decay – corrected activity * ml
tissue)/(activity injected * body weight). We used the
maximum SUV (SUVmax) in order to minimize the par-
tial volume effect. Therefore, we took into account the
following parameters:
1. SUVmax of the tumor
2. Individual variation in SUVmax (ΔSUV) of the
tumor, expressed as a percentage of the baseline
3. SUVmax of the lymph nodes4. Individual variation in SUVmax (ΔSUV) of the
lymph nodes, expressed as a percentage of the
baseline value
5. Metabolic Tumor Volume (MTV), expressed in cc,
obtained directly from the Philips workstation. Each
tumor identified by the user was segmented
automatically in three dimensions by the software
using the following procedure. First, the voxel of
maximum intensity along the selected projection
line is used as the starting point for a region
growing procedure. The algorithm then finds the
voxel of local maximum intensity within a specified
radius (default value of 1 cm) of the starting voxel.
The region growing algorithm then defines the
segmented volume as all voxels connected to the
local maximum intensity voxel that have an intensity
greater than a specified fraction of the maximum
intensity. The threshold intensity value used in this
study was 50% of the local maximum intensity.
Once all of the hypermetabolic tumor foci are
segmented, the software calculates the MTV, defined
as the total volume of all tumors in the body in
milliliters, as well as the maximum and average SUV
within the MTV [14,15].
6. Individual variation in MTV (ΔMTV), expressed as
a percentage of the baseline value
7. Metabolic response, according to the EORTC
criteria [16], comparing the three PET-CT studies.
Statistical analysis
The Systat 10.2 software (Systat inc., Point Richmond
CA) was used for statistical analysis. Student’s paired t-
test was used to compare the SUVmax and MTV at dif-
ferent time points. A p-value <0.05 was considered to
indicate statistical significance. A linear regression ana-
lysis was performed to check out a possible relation be-
tween the metabolic response and the cumulative
radiation doses reached in individual patients at the time
of the during-RT PET-CT study. The disease-free sur-
vival (DFS; time to local or distant event) ‘time to event’
curve was calculated with the Kaplan–Meier method
and statistical significance of the difference was assessed
with the log-rank test.
Results
Table 1 reports the clinical characteristics of all patients.
Pre-RT PET-CT was available in 25/25 patients. During-
RT PET-CT was available in 17/25 patients and no infor-
mation was available for 8 patients due to logistic (3
patients) or technical problems (2 patients), and medical
reasons (3 patients: hyperglycemia and radiation-related
esophagitis). Post-RT PET-CT results were available for
21/25 patients and no information was available for 4
patients due to technical problems (1 patient) or clinical
Table 1 Patient characteristics







1 F 43 Adenocarcinoma T3N2M0 SMD PMR yes T3N1M0
2 M 53 Adenocarcinoma T2N1M0 PMR PMR yes T2N0M0
3 F 54 Adenocarcinoma T4N0M0 PMR PMR yes T1N0M0
4 M 59 SCC T2N2M0 PMR CMR yes T1N1M0
5 F 60 Adenocarcinoma T4N2M0 PMR PMR yes T1N0M0
6 M 60 SCC T3N2M0 PMR CMR yes T1N0M0
7 M 64 Large cell carcinoma T2N1M0 PMR CMR yes T0N2M0
8 M 65 SCC T4N1M0 PMR PMR no
9 F 77 Adenocarcinoma T4N2M0 PMR PMR no
10 M 78 SCC T3N2M0 PMR CMR yes T1N0M0
11 M 62 Adenocarcinoma T4N2M0 SMD PMR no
12 M 70 Adenocarcinoma T4N3M0 PMR PMR no
13 M 73 SCC T3N2M0 PMR PMR no
14 M 55 Adenocarcinoma T4N0M0 SMD † no
15 M 58 Adenocarcinoma T2N2M0 No scan CMR yes T3N2M0
16 M 62 Large cell carcinoma T4N2M0 PMR No scan yes T3N0M0
17 M 63 Adenocarcinoma T4N2M0 No scan CMR yes T0N0M0
18 M 69 Adenocarcinoma T3N2M0 No scan CMR yes T0N0M0
19 M 71 SCC T2N1M0 No scan PMR no
20 M 62 SCC T4N2M0 No scan PMR no
21 M 69 SCC T4N2M0 SMD † no
22 M 68 SCC T2N0M0 PMR † no
23 M 74 Adenocarcinoma T4N3M0 No scan PMR no
24 M 63 Adenocarcinoma T3N2M0 No scan SMD no
25 M 65 SCC T3N0M0 No scan CMR yes T1N0M0
SCC, squamous cell carcinoma; CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease. †Patient died within 70 days
after radiotherapy.
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tion for 1 patient, and pulmonary infection in 2 patients).
18 F-FDG metabolic changes
Figure 1 reports the mean value (±SD) of the SUVmax in
the tumor (A) and lymph nodes (B), and the MTV (C) at
different time-points. At pre-RT PET-CT, the mean value
of SUVmax of the tumor was 16.1± 6.0 with a significant
(p= 0.0001) reduction at during-RT PET-CT (10± 4.6). At
post-RT PET-CT, the mean value of SUVmax of the
tumor was 4.7 ± 2.6, a significant reduction when com-
pared with either pre-RT PET-CT or during-RT PET-CT
values: p = 0.0000, p = 0.005, respectively. At pre-RT PET-
CT, the mean value of SUVmax of the lymph nodes was
7.7 ± 6.0, decreasing to 4.6 ± 4.0 at during-RT PET-CT
(p= 0.06). At post-RT PET-CT, the SUVmax of the lymph
nodes was 2.1 ± 1.6 showing a significant reduction when
compared with either pre-RT PET-CT or during-RT PET-CT values: p< 0.0006, p = 0.02, respectively. At pre-RT
PET-CT, the mean value of MTV was 78.6± 65.6 cc with
a significant (p= 0.002) reduction at during-RT PET-CT
(46.4 ± 40.8 cc). At post-RT PET-CT the MTV was
12± 13.1 cc showing a significant decrease when com-
pared with either pre-RT PET-CT or during-RT PET-CT
values: p = 0.0002, p = 0.002, respectively.
Figure 2 (A, B) reports the values of SUVmax and
ΔSUV of the tumors measured in all three 18 F-FDG stud-
ies at different time points in all patients; Figure 3 (A, B)
reports the values of SUVmax and ΔSUV in the lymph
nodes measured in all three 18 F-FDG studies in all
patients; Figure 4 (A, B) reports the values of MTV and
ΔMTV in the tumors measured in the three 18 F-FDG
studies in all patients. A large heterogeneity in SUVmax,
in ΔSUV, in MTV, and in ΔMTV values was observed
among patients in the tumors, as well as in the lymph
nodes before, during and after chemo-radiotherapy.
Figure 1 Mean value (±SD) of the SUVmax in the tumor (A) and lymph nodes (B), and the MTV (C) at different time-points in all
patients (n = 25).
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tumor measured at during-RT PET-CT and the total dose
of radiotherapy reached at the moment of the scan. A sig-
nificant correlation (r = 0.53, p = 0.001) was found between
SUVmax and the dose of radiotherapy delivered.
When applying the EORTC criteria [16] at during-RT
PET-CT, 13/17 patients (76.5%) showed a partial meta-
bolic response, and 4/17 patients (23.5%) a stable dis-
ease; no complete metabolic response was observed.
When applying the EORTC criteria at post-RT PET-CT,
8/21 patients (38%) showed a complete metabolic re-
sponse, 12/21 patients (57%) a partial metabolic re-
sponse, and one patient (5%) showed stable disease
(Table 1). When analyzing only the subset of patients for
whom all three PET-CT were available (n = 13), we
observed that the metabolic modifications were similar
to those obtained in all series (see Table 1, Figure 1 and
Figure 6): SUVmax of the tumor and of the lymph
nodes, as well as the MTV, significantly decreased dur-
ing and at the end of treatment. A borderline statistically
significant difference (p = 0.05) between non-responders
(n = 7; 12.2 ±5.9) and responders (n = 6; 6.6 ± 2.3) was
found only in SUVmax of the tumor measured at
during-RT PET-CT (Figure 7). There was no significant
correlation between SUVmax of the tumor measured at
during-RT PET-CT and SUVmax measured at post-RTFigure 2 SUVmax (A) and ΔSUV (B, expressed as a percentage of the
18 F-FDG studies in all patients. The black line shows the mean SUVmaxPET-CT, as well as between MTV of the tumor mea-
sured at during-RT PET-CT and MTV measured at
post-RT PET-CT.
Clinical outcome and follow-up
Three out of twenty-five patients (12%) died: one patient
during chemo-RT because of pulmonary infection, be-
fore completing the treatment; two patients died before
undergoing post-RT PET-CT because of myocardial in-
farction and pulmonary infection. Thirteen out of
twenty-five patients (52%) underwent surgery after a me-
dian time of 55 days from the end of treatment: 9/13
(69%) had pathological down-staging to stage 0 (no re-
sidual disease) or stage I, while 4/13 patients (31%)
showed persistent loco-regionally advanced disease at a
hystopathological examination. Tumors in 9/25 patients
(36%) were judged unresectable and treated according to
the preference of the referring physician.
After a median follow-up from the start of chemo-
radiotherapy of 24.7 months (range 7–28 months), 12/
25 patients (48%) are still alive while 13/25 patients
(52%) died with a median survival time of 14 months.
Fifteen patients showed disease progression (7 locoregio-
nal failures, 4 distant metastases and 4 both loco-
regional and distant failures) during follow-up. Median
disease progression free survival time was 13 months.baseline value) values of the primary tumor detected in all three
of the group.
Figure 3 SUVmax (A) and ΔSUV (B, expressed as a percentage of the baseline value) values of the lymph nodes detected in all three
18 F-FDG studies in all patients. The black line shows the mean SUVmax of the group.
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Figure 8 reports the disease progression free survival
time in patients with complete metabolic response and
in patients with no response at post-RT PET-CT,
according to EORTC criteria. The disease progression
free survival time was significantly longer (p = 0.01) in
patients who showed a complete metabolic response
than in patients with partial/stable metabolic response.
No other significant correlation with survival end-
points (local and/or distant disease progression free
survival and overall survival) was found for any other
metabolic parameters evaluated at any different time-
points. In patients who underwent surgery, no sig-
nificant association was observed between pathologic
down-staging and metabolic response.
Discussion
18 F-FDG PET detects metabolic modifications which are
well known to occur before morphologic ones; therefore
functional imaging allows an evaluation of the tumor
metabolic response during radiotherapy earlier than
morphologic imaging [13,16,17]. Changes in therapy,
such as dose-escalation or the addition of another treat-
ment modality may be contemplated for patients whoFigure 4 MTV (A) and ΔMTV (B, expressed as a percentage of the bas
18 F-FDG studies in all patients. The black line shows the mean MTVmaxshow poor response to the current radiotherapy regimen
[18]. Furthermore, a disease reduction during radiother-
apy detected by functional imaging might suggest a radi-
ation dose escalation, whilst remaining within normal
tissue constraints [19]. The role of 18 F-FDG in assessing
the response to non-surgical treatment in patients with
NSCLC has been extensively investigated. Many Authors
performed an 18 F-FDG scan at least two months from
the end of radiotherapy or chemotherapy [10,20–22],
while only a few have evaluated the potential role of
repeating 18 F-FDG PET earlier, either during or after
therapy [13,17,23,24]. Researchers from the University of
Michigan [13] have performed repeated 18 F-FDG PET
in 15 patients with NSCLC stages I to III before, during
and after a course of radiotherapy (or chemo-
radiotherapy) with conventional fractionation. The
Authors have observed a reduction of the peak tumor
18 F-FDG activity at approximately 45 Gy during radio-
therapy, with a further reduction on PET performed
three months from the end of treatment. The qualitative
response during radiotherapy correlated with the overall
response post-radiotherapy, and the peak tumor 18 F-
FDG activity during radiotherapy correlated with that
3 months post-therapy. Subsequently, the same Authorseline value) values of the primary tumor detected in all three
of the group.
Figure 5 Correlation (r = 0.53, p = 0.001) between the SUVmax
of the primary tumor obtained at 18 F-FDG during-RT and the
total dose of radiotherapy reached at the moment of PET.
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apy plan based on 18 F-FDG PET at approximately 45 Gy
during radiotherapy, might allow escalating the tumor
dose without increasing the normal tissue complication
probability. Van Baardwijk et al. [17] investigated
changes in 18 F-FDG uptake in 23 patients with medic-
ally inoperable or advanced NSCLC who underwent serial
18 F-FDG PET-CT scans before treatment, 1 week and
2 weeks after the start of treatment and 70 days from
the end of an accelerated (1.8 Gy twice a day) radiation
treatment with radical intent. While 70 days after the
end of radiotherapy, the metabolic activity of the tumor
significantly decreased compared to the baseline, during
the first 2 weeks of treatment the 18 F-FDG uptake with-
in the tumor changed only moderately (a slight increase
during the first week, and a slight decrease during the
second week). More recently, Giovacchini et al. [25]
performed four repeated 18 F-FDG PET-CT scans in 6
patients undergoing radical radiation treatment for ei-
ther locally advanced or medically inoperable NSCLC.
18 F-FDG PET-CT scans were performed before, during
radiotherapy at the delivered dose of 50 Gy, and after ap-
proximately one month and 3 months from the end ofFigure 6 SUVmax (A) and MTV (B) values of the primary tumor detec
and non-responders (n = 7, red lines) patients.radiotherapy. Radiotherapy induced a progressive de-
crease in glucose metabolism that was greater 3 months
after the end of treatment, but could even be detected
during the treatment itself.
In this study, we have evaluated the metabolic changes
on serial 18 F-FDG PET-CT performed before, during
and after concurrent chemo-radiotherapy in patients
with unresectable or locally advanced non-small-cell-
lung-cancer (NSCLC). We have also correlated the
metabolic changes with the delivered radiation dose, and
with the clinical outcome. 18 F-FDG PET-CT studies
were performed earlier both during treatment, at a me-
dian time of 17 days from the start (median dose of
23.4 Gy), and after treatment at a median time of
30 days. First of all, we observed that at pre-RT PET-CT
the values of SUVmax of the tumors were much higher
than those reported in literature [13,17], similar only to
those reported by Giovacchini et al. [25]. The enhanced
trapping of 18 F-FDG into the tumor cells can be due to
either biological mechanisms, such as the up-regulation
of glucose transporters and hexokinase enzymes, tumor
aggressivity, hypoxia, etc., or to modifications induced
by previous treatment [26–29]. Up to now, however, it is
not known which of these mechanisms is responsible for
the variable levels of 18 F-FDG uptake. In our study, the
large tumor size, containing small areas of necrosis, and
the relatively small number of patients who received pre-
vious treatment could explain the higher values of SUV
at pre-RT PET-CT. From our data, we can observe that
the tumor metabolic activity significantly decreased early
during chemo-RT, and decreased even more at the end
of treatment. The metabolic reduction was significant
for all parameters, but more significant for the SUVmax.
It can be argued that chemo-radiotherapy works better
and faster in the cellular metabolism, when considering
SUV values, and “relatively” less and more slowly in the
tumor volume, based on MTV values. In fact MTV may
be considered a “functional volume” and, as such,ted in all three 18 F-FDG studies in responders (n = 6, blue lines)
Figure 7 Mean value (±SD) of the SUVmax in the primary tumor measured at during-RT PET-CT in responders (n = 6) and non-
reponders (n =7) patients.
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fore, SUVmax is the more sensitive parameter to show
an earlier metabolic modification induced by the treat-
ment. The difference in SUVmax reduction between
pre-RT PET-CT and during-RT PET-CT was signifi-
cantly higher (p = 0.0001) than that observed between
during-RT PET-CT and post-RT PET-CT (p = 0.005).
This interesting finding allow us to speculate that the
tumor cells have a prompt response to treatment. On
the contrary, the MTV reduction was similar betweenFigure 8 Disease progression free survival time according to
metabolic response (EORTC criteria) after chemo-RT.
CMR= complete metabolic response.during-RT PET-CT and post-RT PET-CT (p = 0.002, re-
spectively), supporting the concept that MTV is a func-
tional volume and its response to therapy is slower.
Regarding the lymph nodes, their metabolic activity
tends to decline during chemo-radiotherapy, decreasing
significantly only at the end of treatment. This finding
suggests the stronger lymph node resistance to therapy:
in fact it is well known that the neoplastic lymph nodes
are a negative prognostic factor especially in patients
with NSCLC [30].
Finally, the tumor metabolic activity significantly
decreased after a cumulative radiotherapy dose of only
23.4 Gy, which is much lower than that reported in lit-
erature: 45 Gy and 50 Gy [13,25]. On the other hand,
van Baardwijk et al. [17] did not observe any significant
decrease in tumor metabolic activity after the delivery of
approximately 37 Gy of accelerated radiotherapy (1.8 Gy
twice a day). Differences in the radiotherapy fraction-
ation schedule, treatment time, concurrent chemother-
apy administration, tumor biology, and absolute pre-RT
PET-CT SUVmax values, might have an impact on
tumor 18 F-FDG uptake during radiotherapy. Similarly to
Kong et al. [13] and van Baardwijk et al. [17], we
observed a large heterogeneity in the changes in meta-
bolic activity among individual patients during and after
radiotherapy: this finding may somehow reflect the dif-
ference in radio-responsiveness between the individual
tumors. Similarly to these Authors [13,17], we also
observed a large heterogeneity in the metabolic activity
among the individual patients before treatment, suggest-
ing a large cellular heterogeneity in each tumor: for this
reason we have also utilized ΔSUV and ΔMTV in order
to take into account the “individual” variations during
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lute” values such as SUVmax and MTV. In fact, the in-
dividual variations allow a better measurement of the
effects of the treatment “normalizing” the baseline
values, especially when they are highly heterogeneuos.
Regarding the metabolic response after treatment, the
EORTC criteria [16] classifies the metabolic response on
the basis of SUV values. The classification into four cat-
egories using only a number as cut-off, may sometimes
give an incorrect classification. In fact, the number does
not take into account some scintigraphic features, such
as the distribution and shape of the 18 F-FDG activity.
From our data, the high number of partial metabolic
responses (>50%) can be also attributed to the use of
strict SUV criteria, as proposed by EORTC. Therefore,
from a clinical point of view, we strongly support the ne-
cessity to integrate the SUV values with qualitative and
morphological (CT) analyses of the images since the
confounding effects such as inflammation may be
present at any time after treatment. A wrong classifica-
tion might therefore be avoided and a clinical signifi-
cance could be given to the 18 F-FDG uptake. Both Kong
et al. [13] and van Baardwijk et al. [17], observed an as-
sociation between tumor metabolic response during
radiotherapy and that post treatment, with different pat-
terns of response during radiotherapy for patients with a
complete metabolic response, and patients with a per-
sistence of metabolic activity after the therapy. Our
results do not confirm these findings. We found a bor-
derline statistical significant difference (p = 0.05) only in
SUVmax of the tumor during treatment: non-
responders showed higher value of SUVmax of the
tumor at during-RT PET-CT when compared to respon-
ders patients. Unfortunately, our group sample is too
small to speculate on this finding. Moreover the wide
range in the cumulative radiation dose delivered until
the moment of during-RT PET-CT acquisition (14.4-
34.2 Gy) is likely to have contributed to the heterogen-
eity in metabolic response, and may represent a major
drawback for this study. Indeed, we observed a signifi-
cant correlation between SUVmax measured during-RT
PET-CT and the cumulative dose of radiotherapy deliv-
ered at the moment of the scan acquisition. Although
this finding is not surprising, and is in accordance with
the well-known association between the radiation dose
delivered and the probability of cure in NSCLC [31], this
is the first time that it is clearly shown in a clinical set-
ting. Further investigations of this association, i.e. de-
scribing tumor activity as a function of pre-treatment
activity, radiotherapy dose delivered, and time since the
beginning of radiotherapy, may prove to be very interest-
ing. For example, dose-SUV curves could be elaborated
using experimental data to extrapolate the total radiation
dose required to obtain a complete metabolic responsein each patient, thus making it possible to adapt the ra-
diation dose prescription.
A significant correlation between the residual 18 F-
FDG uptake within the tumor at the end of treatment
(or change in 18 F-FDG uptake in respect to the base-
line), and survival end-points has been described by sev-
eral Authors [10,17]. Finally, also in our experience,
patients with loco-regionally advanced NSCLC who
showed a complete metabolic response at post-RT PET-
CT had a longer disease-free survival when compared
with those with a persisting 18 F-FDG uptake. The main
limitation of this study is the small group of patients.
More studies on a larger number of patients are neces-
sary to confirm our findings.
Conclusions
18 F-FDG PET-CT is able to detect earlier metabolic
modifications in patients with locally advanced NSCLC
who underwent pre-operative concurrent chemo-
radiotherapy. SUVmax of the tumor is therefore a valu-
able parameter, much more so than MTV. While the
metabolic changes of the tumor at the end of treatment
seem to be of prognostic value for a progression disease-
free survival, the metabolic changes during radiotherapy
did not correlate either with the metabolic response after
treatment or with the clinical outcome. However, we
cannot conclude that 18 F-FDG PET-CT during chemo-
radiotherapy does not provide any useful information.
Indeed, our analysis has a major limitation, due to the
wide range in radiation dose reached at the moment of
the PET-CT scan, which may have impaired the inter-
pretation of the results. Further studies exploiting the
correlation between metabolic modifications during
therapy and the clinical outcome are needed in order to
optimize therapeutic strategy. Since the metabolic activ-
ity during chemo-radiotherapy correlates with the cumu-
lative dose of radiotherapy delivered at the moment of
the scan, special attention should be paid to methodo-
logical aspects, such as the radiation dose reached at the
time of the PET scan.
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